Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.
The primary objectives of this study were to assess the immunogenicity and the tolerance of the heptavalent pneumococcal conjugate vaccine (Prevenar) in young infants (2 months of age) with sickle cell disease when administred at 2,3, and 4 months of age.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||An Open, Multicenter Clinical Trial to Investigate the Immunogenicity and Safety of the Pneumococcal 7-Valent Conjugate Vaccine (PREVENAR) in Sickle Cell Disease Infants.|
- Antibody responses to pneumococcal capsular polysaccharides antigens contained in PCV7 vaccine; local and systemic reactions.
- Opsonophagocytic activity; S. pneumoniae nasopharyngeal carriage.
|Study Start Date:||May 2001|
|Estimated Study Completion Date:||November 2002|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00368186
|Paris, France, 75019|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|